Trinity Biotech has unveiled promising clinical data for its upcoming CGM+ continuous glucose monitoring system, showing it can operate without the need for fingerstick calibration. The CGM+ delivers accurate readings over a 15-day lifespan, uses fewer disposable components, and comes at a lower cost.
The subdermal glucose reader—positioned as the company’s flagship product—will also feature modular sensors to monitor pulse rate, sleep, and steps. CEO John Gillard called the achievement “the most significant technical milestone” since acquiring the CGM technology, crediting sensor design improvements, refined signal processing, and proprietary operational enhancements for eliminating calibration requirements.
According to Gillard, the CGM+ now matches market leader standards while offering a unique, affordable, reusable, and sustainable architecture, with integrated tracking for heart activity, body temperature, and physical activity.
The pre-pivotal trial focused solely on the glucose sensor, marking a step toward entering the $13 billion global CGM market—expected to reach $28 billion by 2030. Trinity Biotech plans a mid-2026 commercial launch.